APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Human Single-Cell Multi-Omics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Single-Cell Multi-Omics Market Outlook and Growth Opportunities 2026

Report ID 174000120431 December 2025193 pages

Choose your research edition.

Industry ResearchHuman Single-Cell Multi-Omics Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Single-Cell Multi-Omics Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Human Single-Cell Multi-Omics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Single-Cell Multi-Omics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Single-Cell Multi-Omics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Human Single-Cell Multi-Omics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Single-Cell Multi-Omics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Single-Cell Multi-Omics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Single-Cell Multi-Omics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Single-Cell Multi-Omics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Single-Cell Multi-Omics market include 10x Genomics, 1CellBio, BGI Genomics, Bio-Rad Laboratories, Celsee, Fluidigm Corporation, Fluxion Biosciences, MissionBio and NanoString Technologies, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Human Single-Cell Multi-Omics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Single-Cell Multi-Omics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Single-Cell Multi-Omics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Human Single-Cell Multi-Omics market.

Human Single-Cell Multi-Omics Segment by Company

10x Genomics

1CellBio

BGI Genomics

Bio-Rad Laboratories

Celsee

Fluidigm Corporation

Fluxion Biosciences

MissionBio

NanoString Technologies

Takara Bio

Human Single-Cell Multi-Omics Segment by Type

Single-Cell Proteomics

Single-Cell Genomics

Single-Cell Transcriptomics

Human Single-Cell Multi-Omics Segment by Application

Synthetic Biology

Clinical Research

Translational Research

Human Single-Cell Multi-Omics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Human Single-Cell Multi-Omics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Human Single-Cell Multi-Omics key companies, revenue, market share, and recent developments.

3. To split the Human Single-Cell Multi-Omics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Human Single-Cell Multi-Omics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Single-Cell Multi-Omics significant trends, drivers, influence factors in global and regions.

6. To analyze Human Single-Cell Multi-Omics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Single-Cell Multi-Omics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Single-Cell Multi-Omics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Single-Cell Multi-Omics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Single-Cell Multi-Omics industry.

Chapter 3: Detailed analysis of Human Single-Cell Multi-Omics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Human Single-Cell Multi-Omics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Human Single-Cell Multi-Omics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Single-Cell Multi-Omics Industry Trends Table 2. Human Single-Cell Multi-Omics Industry Drivers Table 3. Human Single-Cell Multi-Omics Industry Opportunities and Challenges Table 4. Human Single-Cell Multi-Omics Industry Restraints Table 5. Global Human Single-Cell Multi-Omics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Single-Cell Multi-Omics Revenue Share by Company (2021-2026) Table 7. Global Human Single-Cell Multi-Omics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Human Single-Cell Multi-Omics Key Company Manufacturing Base & Headquarters Table 9. Global Human Single-Cell Multi-Omics Company, Product Type & Application Table 10. Global Human Single-Cell Multi-Omics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Human Single-Cell Multi-Omics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Single-Cell Proteomics Table 15. Significant Companies of Single-Cell Genomics Table 16. Significant Companies of Single-Cell Transcriptomics Table 17. Global Human Single-Cell Multi-Omics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Human Single-Cell Multi-Omics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Human Single-Cell Multi-Omics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Human Single-Cell Multi-Omics Sales Value Share by Type (2021-2026) Table 21. Global Human Single-Cell Multi-Omics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Synthetic Biology Table 23. Significant Companies of Clinical Research Table 24. Significant Companies of Translational Research Table 25. Global Human Single-Cell Multi-Omics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Human Single-Cell Multi-Omics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Human Single-Cell Multi-Omics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Human Single-Cell Multi-Omics Sales Value Share by Application (2021-2026) Table 29. Global Human Single-Cell Multi-Omics Sales Value Share by Application (2027-2032) Table 30. Global Human Single-Cell Multi-Omics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Human Single-Cell Multi-Omics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Human Single-Cell Multi-Omics Sales Value Share by Region (2021-2026) Table 33. Global Human Single-Cell Multi-Omics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Human Single-Cell Multi-Omics Sales Value Share by Region (2027-2032) Table 35. Global Human Single-Cell Multi-Omics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Human Single-Cell Multi-Omics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Human Single-Cell Multi-Omics Sales Value Market Share by Country (2021-2026) Table 38. Global Human Single-Cell Multi-Omics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Human Single-Cell Multi-Omics Sales Value Market Share by Country (2027-2032) Table 40. 10x Genomics Company Information Table 41. 10x Genomics Business Overview Table 42. 10x Genomics Human Single-Cell Multi-Omics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. 10x Genomics Human Single-Cell Multi-Omics Product Portfolio Table 44. 10x Genomics Recent Development Table 45. 1CellBio Company Information Table 46. 1CellBio Business Overview Table 47. 1CellBio Human Single-Cell Multi-Omics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. 1CellBio Human Single-Cell Multi-Omics Product Portfolio Table 49. 1CellBio Recent Development Table 50. BGI Genomics Company Information Table 51. BGI Genomics Business Overview Table 52. BGI Genomics Human Single-Cell Multi-Omics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. BGI Genomics Human Single-Cell Multi-Omics Product Portfolio Table 54. BGI Genomics Recent Development Table 55. Bio-Rad Laboratories Company Information Table 56. Bio-Rad Laboratories Business Overview Table 57. Bio-Rad Laboratories Human Single-Cell Multi-Omics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Bio-Rad Laboratories Human Single-Cell Multi-Omics Product Portfolio Table 59. Bio-Rad Laboratories Recent Development Table 60. Celsee Company Information Table 61. Celsee Business Overview Table 62. Celsee Human Single-Cell Multi-Omics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Celsee Human Single-Cell Multi-Omics Product Portfolio Table 64. Celsee Recent Development Table 65. Fluidigm Corporation Company Information Table 66. Fluidigm Corporation Business Overview Table 67. Fluidigm Corporation Human Single-Cell Multi-Omics Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Fluidigm Corporation Human Single-Cell Multi-Omics Product Portfolio Table 69. Fluidigm Corporation Recent Development Table 70. Fluxion Biosciences Company Information Table 71. Fluxion Biosciences Business Overview Table 72. Fluxion Biosciences Human Single-Cell Multi-Omics Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Fluxion Biosciences Human Single-Cell Multi-Omics Product Portfolio Table 74. Fluxion Biosciences Recent Development Table 75. MissionBio Company Information Table 76. MissionBio Business Overview Table 77. MissionBio Human Single-Cell Multi-Omics Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. MissionBio Human Single-Cell Multi-Omics Product Portfolio Table 79. MissionBio Recent Development Table 80. NanoString Technologies Company Information Table 81. NanoString Technologies Business Overview Table 82. NanoString Technologies Human Single-Cell Multi-Omics Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. NanoString Technologies Human Single-Cell Multi-Omics Product Portfolio Table 84. NanoString Technologies Recent Development Table 85. Takara Bio Company Information Table 86. Takara Bio Business Overview Table 87. Takara Bio Human Single-Cell Multi-Omics Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Takara Bio Human Single-Cell Multi-Omics Product Portfolio Table 89. Takara Bio Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Human Single-Cell Multi-Omics Product Image Figure 2. Global Human Single-Cell Multi-Omics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Single-Cell Multi-Omics Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Single-Cell Multi-Omics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Single-Cell Proteomics Image Figure 8. Single-Cell Genomics Image Figure 9. Single-Cell Transcriptomics Image Figure 10. Global Human Single-Cell Multi-Omics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Human Single-Cell Multi-Omics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Human Single-Cell Multi-Omics Sales Value Share by Type (2021-2032) Figure 13. Synthetic Biology Image Figure 14. Clinical Research Image Figure 15. Translational Research Image Figure 16. Global Human Single-Cell Multi-Omics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Human Single-Cell Multi-Omics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Human Single-Cell Multi-Omics Sales Value Share by Application (2021-2032) Figure 19. Global Human Single-Cell Multi-Omics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Human Single-Cell Multi-Omics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Human Single-Cell Multi-Omics Sales Value (2021-2032) & (US$ Million) Figure 22. North America Human Single-Cell Multi-Omics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Human Single-Cell Multi-Omics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Human Single-Cell Multi-Omics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Human Single-Cell Multi-Omics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Human Single-Cell Multi-Omics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Human Single-Cell Multi-Omics Sales Value (2021-2032) & (US$ Million) Figure 28. South America Human Single-Cell Multi-Omics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Human Single-Cell Multi-Omics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Human Single-Cell Multi-Omics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Single-Cell Proteomics
  • Single-Cell Genomics
  • Single-Cell Transcriptomics
Applications
  • Synthetic Biology
  • Clinical Research
  • Translational Research
Companies covered
  • 10x Genomics
  • 1CellBio
  • BGI Genomics
  • Bio-Rad Laboratories
  • Celsee
  • Fluidigm Corporation
  • Fluxion Biosciences
  • MissionBio
  • NanoString Technologies
  • Takara Bio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Single-Cell Multi-Omics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Single-Cell Multi-Omics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Human Single-Cell Multi-Omics Market Dynamics
  1. 2.1 Human Single-Cell Multi-Omics Industry Trends
  2. 2.2 Human Single-Cell Multi-Omics Industry Drivers
  3. 2.3 Human Single-Cell Multi-Omics Industry Opportunities and Challenges
  4. 2.4 Human Single-Cell Multi-Omics Industry Restraints
3 Human Single-Cell Multi-Omics Market by Company
  1. 3.1 Global Human Single-Cell Multi-Omics Company Revenue Ranking in 2025
  2. 3.2 Global Human Single-Cell Multi-Omics Revenue by Company (2021-2026)
  3. 3.3 Global Human Single-Cell Multi-Omics Company Ranking (2024-2026)
  4. 3.4 Global Human Single-Cell Multi-Omics Company Manufacturing Base and Headquarters
  5. 3.5 Global Human Single-Cell Multi-Omics Company Product Type and Application
  6. 3.6 Global Human Single-Cell Multi-Omics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Human Single-Cell Multi-Omics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Human Single-Cell Multi-Omics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Human Single-Cell Multi-Omics Market by Type
  1. 4.1 Human Single-Cell Multi-Omics Type Introduction
  2. 4.1.1 Single-Cell Proteomics
  3. 4.1.2 Single-Cell Genomics
  4. 4.1.3 Single-Cell Transcriptomics
  5. 4.2 Global Human Single-Cell Multi-Omics Sales Value by Type
  6. 4.2.1 Global Human Single-Cell Multi-Omics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Human Single-Cell Multi-Omics Sales Value by Type (2021-2032)
  8. 4.2.3 Global Human Single-Cell Multi-Omics Sales Value Share by Type (2021-2032)
5 Human Single-Cell Multi-Omics Market by Application
  1. 5.1 Human Single-Cell Multi-Omics Application Introduction
  2. 5.1.1 Synthetic Biology
  3. 5.1.2 Clinical Research
  4. 5.1.3 Translational Research
  5. 5.2 Global Human Single-Cell Multi-Omics Sales Value by Application
  6. 5.2.1 Global Human Single-Cell Multi-Omics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Single-Cell Multi-Omics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Human Single-Cell Multi-Omics Sales Value Share by Application (2021-2032)
6 Human Single-Cell Multi-Omics Regional Value Analysis
  1. 6.1 Global Human Single-Cell Multi-Omics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Single-Cell Multi-Omics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Human Single-Cell Multi-Omics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Human Single-Cell Multi-Omics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Single-Cell Multi-Omics Sales Value (2021-2032)
  7. 6.3.2 North America Human Single-Cell Multi-Omics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Human Single-Cell Multi-Omics Sales Value (2021-2032)
  10. 6.4.2 Europe Human Single-Cell Multi-Omics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Human Single-Cell Multi-Omics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Human Single-Cell Multi-Omics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Human Single-Cell Multi-Omics Sales Value (2021-2032)
  16. 6.6.2 South America Human Single-Cell Multi-Omics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Human Single-Cell Multi-Omics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Human Single-Cell Multi-Omics Sales Value Share by Country, 2025 VS 2032
7 Human Single-Cell Multi-Omics Country-level Value Analysis
  1. 7.1 Global Human Single-Cell Multi-Omics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Single-Cell Multi-Omics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Human Single-Cell Multi-Omics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Human Single-Cell Multi-Omics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Human Single-Cell Multi-Omics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Human Single-Cell Multi-Omics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Human Single-Cell Multi-Omics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 10x Genomics
  2. 8.1.1 10x Genomics Company Information
  3. 8.1.2 10x Genomics Business Overview
  4. 8.1.3 10x Genomics Human Single-Cell Multi-Omics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 10x Genomics Human Single-Cell Multi-Omics Product Portfolio
  6. 8.1.5 10x Genomics Recent Developments
  7. 8.2 1CellBio
  8. 8.2.1 1CellBio Company Information
  9. 8.2.2 1CellBio Business Overview
  10. 8.2.3 1CellBio Human Single-Cell Multi-Omics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 1CellBio Human Single-Cell Multi-Omics Product Portfolio
  12. 8.2.5 1CellBio Recent Developments
  13. 8.3 BGI Genomics
  14. 8.3.1 BGI Genomics Company Information
  15. 8.3.2 BGI Genomics Business Overview
  16. 8.3.3 BGI Genomics Human Single-Cell Multi-Omics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 BGI Genomics Human Single-Cell Multi-Omics Product Portfolio
  18. 8.3.5 BGI Genomics Recent Developments
  19. 8.4 Bio-Rad Laboratories
  20. 8.4.1 Bio-Rad Laboratories Company Information
  21. 8.4.2 Bio-Rad Laboratories Business Overview
  22. 8.4.3 Bio-Rad Laboratories Human Single-Cell Multi-Omics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bio-Rad Laboratories Human Single-Cell Multi-Omics Product Portfolio
  24. 8.4.5 Bio-Rad Laboratories Recent Developments
  25. 8.5 Celsee
  26. 8.5.1 Celsee Company Information
  27. 8.5.2 Celsee Business Overview
  28. 8.5.3 Celsee Human Single-Cell Multi-Omics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Celsee Human Single-Cell Multi-Omics Product Portfolio
  30. 8.5.5 Celsee Recent Developments
  31. 8.6 Fluidigm Corporation
  32. 8.6.1 Fluidigm Corporation Company Information
  33. 8.6.2 Fluidigm Corporation Business Overview
  34. 8.6.3 Fluidigm Corporation Human Single-Cell Multi-Omics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fluidigm Corporation Human Single-Cell Multi-Omics Product Portfolio
  36. 8.6.5 Fluidigm Corporation Recent Developments
  37. 8.7 Fluxion Biosciences
  38. 8.7.1 Fluxion Biosciences Company Information
  39. 8.7.2 Fluxion Biosciences Business Overview
  40. 8.7.3 Fluxion Biosciences Human Single-Cell Multi-Omics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Fluxion Biosciences Human Single-Cell Multi-Omics Product Portfolio
  42. 8.7.5 Fluxion Biosciences Recent Developments
  43. 8.8 MissionBio
  44. 8.8.1 MissionBio Company Information
  45. 8.8.2 MissionBio Business Overview
  46. 8.8.3 MissionBio Human Single-Cell Multi-Omics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 MissionBio Human Single-Cell Multi-Omics Product Portfolio
  48. 8.8.5 MissionBio Recent Developments
  49. 8.9 NanoString Technologies
  50. 8.9.1 NanoString Technologies Company Information
  51. 8.9.2 NanoString Technologies Business Overview
  52. 8.9.3 NanoString Technologies Human Single-Cell Multi-Omics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 NanoString Technologies Human Single-Cell Multi-Omics Product Portfolio
  54. 8.9.5 NanoString Technologies Recent Developments
  55. 8.10 Takara Bio
  56. 8.10.1 Takara Bio Company Information
  57. 8.10.2 Takara Bio Business Overview
  58. 8.10.3 Takara Bio Human Single-Cell Multi-Omics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Takara Bio Human Single-Cell Multi-Omics Product Portfolio
  60. 8.10.5 Takara Bio Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst